The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 1 results of Oncobax-AK in combination with ipilimumab/nivolumab in advanced clear cell renal cell carcinoma (ccRCC; NCT05865730).
 
Lisa Derosa
Consulting or Advisory Role - EverImmune (Inst)
 
Philippe Barthelemy
Honoraria - Astellas Pharma; AstraZeneca; Bayer; BMS; Gilead Sciences; IPSEN; Janssen-Cilag; Merck KGaA; MSD; Novartis; Pfizer
Consulting or Advisory Role - AAA/Endocyte/Novartis; Amgen; AstraZeneca; Bayer; BMS; Eisai; Gilead Sciences; ipsen; Janssen-Cilag; Merck KGaA; MSD Oncology; Pfizer
Research Funding - IPSEN (Inst)
Travel, Accommodations, Expenses - BMS; IPSEN; Janssen-Cilag; Merck/Pfizer; MSD; Pfizer
 
Brigitte Laguerre
No Relationships to Disclose
 
Fabrice Barlesi
Consulting or Advisory Role - Amgen (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Eisai Europe (Inst); Lilly (Inst); Merck Serono (Inst); Mirati Therapeutics (Inst); MSD Oncology (Inst); Novartis (Inst); Roche/Genentech (Inst); Sanofi (Inst); Takeda (Inst)
Research Funding - Abbvie (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Innate Pharma (Inst); Innate Pharma (Inst); Ipsen (Inst); Lilly (Inst); Merck Serono (Inst); MSD Oncology (Inst); Novartis (Inst); Pfizer (Inst); Pierre Fabre (Inst); Roche/Genentech (Inst); Sanofi/Aventis (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Roche/Genentech
 
Bernard Escudier
Honoraria - Ipsen; Oncorena
Consulting or Advisory Role - Ipsen; Oncorena
Travel, Accommodations, Expenses - Ipsen; MSD; Oncrena; Oncrena
 
Laurence Zitvogel
Leadership - EverImmune; Hookipa Biotech; Transgene
Stock and Other Ownership Interests - EverImmune
Honoraria - EverImmune; Hookipa Biotech; Transgene
Consulting or Advisory Role - EverImmune; German Cancer Aid; Hookipa Biotech; Pierre Fabre; Transgene
Research Funding - 9 Meters Biopharma; Biomérieux; Daiichi Sankyo; EverImmune; Pileje; Transgene
Patents, Royalties, Other Intellectual Property - EverImmune
Travel, Accommodations, Expenses - Abbvie; AstraZeneca
Other Relationship - Seerave Foundation
(OPTIONAL) Uncompensated Relationships - MaaT Pharma
 
Laurence Albiges
Consulting or Advisory Role - Astellas Pharma (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo Europe GmbH (Inst); Eisai (Inst); Ipsen (Inst); Janssen (Inst); Merck (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Telix Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - BMS; Ipsen; MSD; Pfizer